Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-09-25 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Dr. Markus Enzelberger), their position ('Member of the managing body'), and specific transaction details (Disposal of shares, price, and volume) occurring on 2018-09-24. This directly matches the definition for Director's Dealing, which corresponds to the filing code DIRS.
2018-09-25 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of a director (Dr. Simon Moroney), their position, and a comprehensive list of share transactions (Disposal) including price, volume, and date. This content directly corresponds to the definition of Director's Dealing reports.
2018-09-21 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition of Director's Dealing, which corresponds to the filing code DIRS. The document details the transaction (Disposal), the person involved (Dr. Simon Moroney, Member of the managing body), and the specific dates and prices of the share transactions.
2018-09-21 English
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a press release dated September 17, 2018, announcing the expansion of a strategic alliance between MorphoSys AG and LEO Pharma regarding peptide-derived therapeutics. It details the terms of the agreement, financial considerations (R&D funding, milestones, royalties), and includes boilerplate information about both companies. This type of announcement, detailing a significant business development or partnership, does not fit the specific definitions for financial reports (10-K, IR, ER, MRQ), governance documents (CGR, DEF 14A), or shareholder actions (AGM-R, DVA). Since it is a corporate news announcement transmitted via DGAP (a service often used for regulatory news), and it describes a significant business event (alliance expansion), it is best classified as a general Regulatory Filing (RNS) or potentially a specific type of corporate news. Given the options, and that it is a formal announcement of a business development rather than a financial result or management change, RNS serves as the most appropriate general regulatory/corporate news category, although it is highly specific news content. However, since it is a detailed news release about a strategic business development (alliance), and not a standard financial filing, RNS (Regulatory Filings / General Regulatory Announcements) is the best fit among the provided codes for non-standard, material corporate news.
2018-09-17 English
MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106 (news with additional features)
Regulatory Filings Classification · 99% confidence The document is titled 'News Details' and begins with a headline announcing the start of a Phase 1 clinical study for a drug (MOR106) involving two companies (MorphoSys and Galapagos). It uses keywords like 'DGAP-News', 'Corporate', 'announcement', and provides contact information typical of a press release or corporate news update. It is not a comprehensive annual report (10-K), an interim report (IR), or a formal regulatory filing like a proxy statement (DEF 14A). Since it is a specific corporate announcement about clinical trial progress, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a news release disseminated via a service (DGAP) that handles regulatory announcements, but doesn't fit the more specific categories like ER, CAP, or DIV. Given the context of clinical trial updates, RNS is the most appropriate general regulatory news category.
2018-09-13 English
MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner (news with additional features)
Legal Proceedings Report Classification · 99% confidence The document is a news release dated September 12, 2018, originating from MorphoSys AG and Galapagos NV, disseminated via DGAP (a service of EQS Group AG). The content announces the U.S. antitrust clearance for a global license agreement (MOR106) with Novartis and provides updated financial guidance for 2018. This type of announcement, detailing a significant corporate event (licensing deal completion) and providing immediate financial impact updates (revenue/EBIT guidance revision), aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of material corporate/financial news rather than a full periodic report (like 10-K or IR), and it contains key financial highlights (guidance update), ER is a strong candidate. However, given the context of a partnership milestone and regulatory clearance, it is fundamentally a material corporate announcement. Since it is not a full periodic report, and it is not explicitly a proxy statement, dividend notice, or director dealing, it fits the general category of a significant corporate news item. In many databases, such material, non-periodic corporate updates are classified as Regulatory Filings (RNS) if they don't fit the specific financial report codes. Given the structure (News Details, DGAP-News header, focus on a transaction milestone and guidance update), it is a material corporate announcement. If 'ER' is strictly for quarterly results, this is better suited as RNS, but the inclusion of revised financial guidance makes ER plausible. I will lean towards RNS as the most appropriate general regulatory announcement category for a major partnership milestone announcement that includes guidance revision, as it is not a standard earnings report.
2018-09-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.